Tdap Vaccine Effectiveness in Adolescents During the 2012 Washington State Pertussis Epidemic

BACKGROUND: Acellular pertussis vaccines replaced whole-cell vaccines for the 5-dose childhood vaccination series in 1997. A sixth dose of pertussis-containing vaccine, tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis, adsorbed (Tdap), was recommended in 2005 for adolescents and adults. Studies examining Tdap vaccine effectiveness (VE) among adolescents who have received all acellular vaccines are limited. METHODS: To assess Tdap VE and duration of protection, we conducted a matched case-control study during the 2012 pertussis epidemic in Washington among adolescents born during 1993–2000. All pertussis cases reported from January 1 through June 30, 2012, in 7 counties were included; 3 controls were matched by primary provider clinic and birth year to each case. Vaccination histories were obtained through medical records, the state immunization registry, and parent interviews. Participants were classified by type of pertussis vaccine received on the basis of birth year: a mix of whole-cell and acellular vaccines (1993–1997) or all acellular vaccines (1998–2000). We used conditional logistic regression to calculate odds ratios comparing Tdap receipt between cases and controls. RESULTS: Among adolescents who received all acellular vaccines (450 cases, 1246 controls), overall Tdap VE was 63.9% (95% confidence interval [CI]: 50% to 74%). VE within 1 year of vaccination was 73% (95% CI: 60% to 82%). At 2 to 4 years postvaccination, VE declined to 34% (95% CI: −0.03% to 58%). CONCLUSIONS: Tdap protection wanes within 2 to 4 years. Lack of long-term protection after vaccination is likely contributing to increases in pertussis among adolescents.

[1]  J. P. Davis,et al.  Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis: evidence of rapidly waning immunity and difference in effectiveness by Tdap brand. , 2014, The Journal of infectious diseases.

[2]  T. Merkel,et al.  Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model , 2013, Proceedings of the National Academy of Sciences.

[3]  M. Tondella,et al.  Prevalence and Molecular Characterization of Pertactin-Deficient Bordetella pertussis in the United States , 2013, Clinical and Vaccine Immunology.

[4]  S. Stokley,et al.  National and State Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2012 , 2013, MMWR. Morbidity and mortality weekly report.

[5]  A. Rowhani-Rahbar,et al.  Effectiveness of pertussis vaccines for adolescents and adults: case-control study , 2013, BMJ.

[6]  C. Locht,et al.  Persistence at one year of age of antigen-induced cellular immune responses in preterm infants vaccinated against whooping cough: comparison of three different vaccines and effect of a booster dose. , 2013, Vaccine.

[7]  C. Kenyon,et al.  Waning Immunity to Pertussis Following 5 Doses of DTaP , 2013, Pediatrics.

[8]  M. Sawyer,et al.  Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap) in Pregnant Women — Advisory Committee on Immunization Practices (ACIP), 2012 , 2013, MMWR. Morbidity and mortality weekly report.

[9]  A. Evangelista,et al.  Pertactin-negative variants of Bordetella pertussis in the United States. , 2013, The New England journal of medicine.

[10]  J. Zipprich,et al.  California pertussis epidemic, 2010. , 2012, The Journal of pediatrics.

[11]  T. Clark,et al.  Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. , 2012, JAMA.

[12]  Bruce Fireman,et al.  Waning protection after fifth dose of acellular pertussis vaccine in children. , 2012, The New England journal of medicine.

[13]  T. Skoff,et al.  Early Impact of the US Tdap vaccination program on pertussis trends. , 2012, Archives of pediatrics & adolescent medicine.

[14]  E. Sanders,et al.  Different IgG-subclass distributions after whole-cell and acellular pertussis infant primary vaccinations in healthy and pertussis infected children. , 2011, Vaccine.

[15]  F. Ahmed,et al.  Barriers to early uptake of tetanus, diphtheria and acellular pertussis vaccine (Tdap) among adults-United States, 2005-2007. , 2011, Vaccine.

[16]  J. Liese,et al.  Acellular Pertussis Booster in Adolescents Induces Th1 and Memory CD8+ T Cell Immune Response , 2011, PloS one.

[17]  T. Clark,et al.  Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine against pertussis. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  R. Veenhoven,et al.  IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content. , 2009, Vaccine.

[19]  H. Quinn,et al.  PERTUSSIS VACCINE EFFECTIVENESS AFTER MASS IMMUNIZATION OF HIGH SCHOOL STUDENTS IN AUSTRALIA , 2009, The Pediatric infectious disease journal.

[20]  Susan Partridge,et al.  Efficacy of an acellular pertussis vaccine among adolescents and adults. , 2005, The New England journal of medicine.

[21]  B. Guyer,et al.  Calling the shots: immunization finance policies and practices. Executive summary of the report of the Institute of Medicine. , 2000, American journal of preventive medicine.

[22]  K. Elkins,et al.  Protective Immunity to Bordetella pertussis Requires Both B Cells and Cd4+ T Cells for Key Functions Other than Specific Antibody Production , 2000, The Journal of experimental medicine.

[23]  A. la Sala,et al.  Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines , 1997, Infection and immunity.

[24]  P. Strebel,et al.  Pertussis vaccination : use of acellular pertussis vaccines among infants and young children : recommendations of the Advisory Committee on Immunization Practices (ACIP). , 1997 .

[25]  National and state vaccination coverage among adolescents aged 13-17 years--United States, 2011. , 2012, MMWR. Morbidity and mortality weekly report.

[26]  S. Brownlee,et al.  Examination of Universal Vaccine Purchasing States and New Jersey , 2005 .

[27]  S. M. Hewitt,et al.  Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP) , 1997, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[28]  Early Release,et al.  Morbidity and Mortality Weekly Report Influenza Vaccination of Health-care Personnel Recommendations of the Healthcare Infection Control Practices Advisory Committee (hicpac) and the Advisory Committee on Immunization Practices (acip) , 2022 .